VMS and Menopause: KNDy Neurons, NK Receptors, and Practical Insights : Episode 2

VMS Symptoms and Neurokinin Receptor Antagonists

November 25, 2024

By Mary Jane Minkin, MD
Lisa Larkin, MD, FACP, MSCP, IF

Opinion

Video

Panelists discuss how neurokinin 3 (NK3) receptors contribute to vasomotor symptoms (VMS) and how antagonism of NK3 receptors with drugs like fezolinetant can effectively reduce VMS, while also exploring the dual receptor action of elinzanetant, which blocks both NK1 and NK3 receptors to improve VMS and associated sleep disturbances.

EP: 1.Overview of KNDy neurons

Now Viewing

EP: 2.VMS Symptoms and Neurokinin Receptor Antagonists

EP: 3.Neurokinin and Estrogen Balance in Menopausal Hot Flashes for Primary Care

EP: 4.Fezolinetant Guidelines and Emerging Data on Menopause and Liver Health

EP: 5.Molecular Comparison and Safety Profiles of Fezolinetant and Elinzanetant

EP: 6.Malignancy Risks of Neurokinin Receptor Antagonists

EP: 7.Guidance for PCPs: Streamlining Menopause Care

EP: 8.Nonestrogen Treatments for Menopause

EP: 9.VMS Treatment Guidelines

What are neurokinin 3 (NK3) receptors, and how can antagonism of NK3 receptors affect VMS?
- What is fezolinetant?

Note: The binding affinity of fezolinetant at NK3 receptors is 450 times greater than those for neurokinin 1 (NK1); this is an NK3 and has no NK1 action

What is elinzanetant?

Note: Elinzanetant is currently under review with the FDA

How can blockade of NK1 and NK3 receptors improve VMS and sleep disturbances associated with menopause?